目的 觀察注射用丹參多酚酸聯(lián)合替羅非班對急性進展性腦梗死患者的NIHSS評分和mRS評分的影響。方法 選擇2017年1月-2019年12月在鄭州市第一人民醫(yī)院治療的急性進展性腦梗死患者82例作為研究對象。將患者依據(jù)入組時間隨機分為對照組和觀察組，每組各41例。對照組前30 min靜脈泵入負(fù)荷劑量鹽酸替羅非班氯化鈉注射液，0.4 μg/（kg·min），后給予0.1 μg/（kg·min）的低劑量維持24 h。觀察組在對照組治療的基礎(chǔ)上靜脈滴注注射用丹參多酚酸，0.13 g加入到250 mL氯化鈉注射液中，1次/d。兩組均治療14 d。觀察并比較兩組患者的美國國立衛(wèi)生研究院卒中量表評分（NIHSS）、改良Rankin量表評分（mRS）和不良反應(yīng)情況。結(jié)果 治療后，兩組NIHSS評分均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療后，觀察組NIHSS評分明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療90 d后隨訪，觀察組mRS評分總有效率為82.9%，顯著高于對照組的61.0%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。兩組患者均未出現(xiàn)嚴(yán)重不良反應(yīng)，在肝功能異常、血小板減少、牙齦出血、皮膚黏膜出血等方面，差異無統(tǒng)計學(xué)意義。結(jié)論 注射用丹參多酚酸聯(lián)合替羅非班能夠減輕急性腦進展性梗死患者神經(jīng)缺損癥狀，改善預(yù)后，且不良反應(yīng)輕，安全性好，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the effect of Salvianolic Acids for Injection combined with tirofiban on NIHSS and mRS scores in patients with acute progressive cerebral infarction. Methods A total of 82 patients with acute progressive cerebral infarction treated in the First People Hospital of Zhengzhou from January 2017 to December 2019 were selected as study subjects. The patients were randomly divided into the control group and the observation group according to the enrollment time, with 41 cases in each group. Patients in the control group were injected intravenously for Tirofiban hydrochloride Sodium Chloride Injection with a loading dose of 0.4 μg/(kg·min) in the first 30 min, and then 0.1 μg/(kg·min) was given as a low dose for 24 h. Patients in the observation group were iv administered with Salvianolic Acids for Injection on the basis of control group, 0.13 g was added to 250 mL sodium chloride injection, once daily. Both groups were treated for 14 d. After treatment, NIHSS score, mRS score, and adverse reactions were observed and compared in two groups. Results After treatment, NIHSS score in two groups were decreased significantly, and the difference before and after treatment in the same group was statistically significant (P<0.05). After treatment, the NIHSS score in the observation group was significantly lower than that in the control group, and the difference between two groups was statistically significant (P<0.05). After 90 days of follow-up, the total effective rate of mRS score in the observation group was 82.9%, which was significantly higher than 61.0% in the control group, and the difference between two groups was statistically significant (P<0.05). There were no serious adverse reactions in two groups, and there were no statistically significant differences in liver function abnormalities, thrombocytopenia, gingival bleeding, skin mucosal bleeding in two groups. Conclusion Salvianolic Acids for Injectioncombined with tirofiban can alleviate nerve defect symptoms and improve prognosis in patients with acute progressive cerebral infarction, with mild adverse reactions and good safety, and certain clinical application value.

R971